These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 31051278)

  • 1. Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis.
    Mezochow A; Thakur KT; Zentner I; Subbian S; Kagan L; Vinnard C
    Int J Infect Dis; 2019 Jul; 84():15-21. PubMed ID: 31051278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naïve-pooled pharmacokinetic analysis of pyrazinamide, isoniazid and rifampicin in plasma and cerebrospinal fluid of Vietnamese children with tuberculous meningitis.
    Pouplin T; Bang ND; Toi PV; Phuong PN; Dung NH; Duong TN; Caws M; Thwaites GE; Tarning J; Day JN
    BMC Infect Dis; 2016 Apr; 16():144. PubMed ID: 27039088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety/tolerability of isoniazid, rifampicin and pyrazinamide in children and adolescents treated for tuberculous meningitis.
    Ruslami R; Gafar F; Yunivita V; Parwati I; Ganiem AR; Aarnoutse RE; Wilffert B; Alffenaar JC; Nataprawira HM
    Arch Dis Child; 2022 Jan; 107(1):70-77. PubMed ID: 34183327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial.
    Cresswell FV; Meya DB; Kagimu E; Grint D; Te Brake L; Kasibante J; Martyn E; Rutakingirwa M; Quinn CM; Okirwoth M; Tugume L; Ssembambulidde K; Musubire AK; Bangdiwala AS; Buzibye A; Muzoora C; Svensson EM; Aarnoutse R; Boulware DR; Elliott AM
    Clin Infect Dis; 2021 Sep; 73(5):876-884. PubMed ID: 33693537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric tuberculous meningitis: Model-based approach to determining optimal doses of the anti-tuberculosis drugs rifampin and levofloxacin for children.
    Savic RM; Ruslami R; Hibma JE; Hesseling A; Ramachandran G; Ganiem AR; Swaminathan S; McIlleron H; Gupta A; Thakur K; van Crevel R; Aarnoutse R; Dooley KE
    Clin Pharmacol Ther; 2015 Dec; 98(6):622-9. PubMed ID: 26260983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial.
    Ruslami R; Ganiem AR; Dian S; Apriani L; Achmad TH; van der Ven AJ; Borm G; Aarnoutse RE; van Crevel R
    Lancet Infect Dis; 2013 Jan; 13(1):27-35. PubMed ID: 23103177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.
    Te Brake L; Dian S; Ganiem AR; Ruesen C; Burger D; Donders R; Ruslami R; van Crevel R; Aarnoutse R
    Int J Antimicrob Agents; 2015 May; 45(5):496-503. PubMed ID: 25703312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningitis.
    Kaojarern S; Supmonchai K; Phuapradit P; Mokkhavesa C; Krittiyanunt S
    Clin Pharmacol Ther; 1991 Jan; 49(1):6-12. PubMed ID: 1988241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic variability and the probability of site of action target attainment during tuberculosis meningitis treatment: A physiologically based pharmacokinetic modeling and simulations study.
    Mehta K; Narayanan N; Heysell SK; Bisson GP; Subbian S; Kurepina N; Kreiswirth BN; Vinnard C
    Tuberculosis (Edinb); 2022 Dec; 137():102271. PubMed ID: 36375279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial.
    Heemskerk D; Day J; Chau TT; Dung NH; Yen NT; Bang ND; Merson L; Olliaro P; Pouplin T; Caws M; Wolbers M; Farrar J
    Trials; 2011 Feb; 12():25. PubMed ID: 21288325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum and cerebrospinal fluid concentrations of rifampicin at two dose levels in children with tuberculous meningitis.
    Mahajan M; Rohatgi D; Talwar V; Patni SK; Mahajan P; Agarwal DS
    J Commun Dis; 1997 Sep; 29(3):269-74. PubMed ID: 9465533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis.
    Ellard GA; Humphries MJ; Allen BW
    Am Rev Respir Dis; 1993 Sep; 148(3):650-5. PubMed ID: 8368635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children.
    Donald PR
    Tuberculosis (Edinb); 2010 Sep; 90(5):279-92. PubMed ID: 20709598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial.
    Wasserman S; Davis A; Stek C; Chirehwa M; Botha S; Daroowala R; Bremer M; Maxebengula M; Koekemoer S; Goliath R; Jackson A; Crede T; Naude J; Szymanski P; Vallie Y; Moosa MS; Wiesner L; Black J; Meintjes G; Maartens G; Wilkinson RJ
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0014021. PubMed ID: 33972248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatifloxacin Pharmacokinetics/Pharmacodynamics-based Optimal Dosing for Pulmonary and Meningeal Multidrug-resistant Tuberculosis.
    Deshpande D; Pasipanodya JG; Srivastava S; Bendet P; Koeuth T; Bhavnani SM; Ambrose PG; Smythe W; McIlleron H; Thwaites G; Gumusboga M; Van Deun A; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S274-S283. PubMed ID: 30496459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Based Meta-analysis of Rifampicin Exposure and Mortality in Indonesian Tuberculous Meningitis Trials.
    Svensson EM; Dian S; Te Brake L; Ganiem AR; Yunivita V; van Laarhoven A; Van Crevel R; Ruslami R; Aarnoutse RE
    Clin Infect Dis; 2020 Nov; 71(8):1817-1823. PubMed ID: 31665299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-Blind, Randomized, Placebo-Controlled Phase II Dose-Finding Study To Evaluate High-Dose Rifampin for Tuberculous Meningitis.
    Dian S; Yunivita V; Ganiem AR; Pramaesya T; Chaidir L; Wahyudi K; Achmad TH; Colbers A; Te Brake L; van Crevel R; Ruslami R; Aarnoutse R
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30224533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population modeling and Monte Carlo simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of rifampin in lungs.
    Goutelle S; Bourguignon L; Maire PH; Van Guilder M; Conte JE; Jelliffe RW
    Antimicrob Agents Chemother; 2009 Jul; 53(7):2974-81. PubMed ID: 19380594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment.
    Stemkens R; Litjens CHC; Dian S; Ganiem AR; Yunivita V; van Crevel R; Te Brake LHM; Ruslami R; Aarnoutse RE
    Int J Antimicrob Agents; 2019 Sep; 54(3):371-374. PubMed ID: 31202922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.